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Introduction
 
In recent years there has been a large increase in
the number of economic evaluations of pharma-
ceuticals [1]. Many of these studies have been
commissioned by individual pharmaceutical com-
panies, in support of new or existing products. Eu-
rope, particularly the countries of the European
Union, represents one of the world’s largest phar-
maceutical markets. Therefore there is consider-
able interest in whether the activities of companies,
in commissioning and undertaking pharmacoeco-
nomics or outcomes research studies, are having
any impact.
The experience in Europe was reviewed earlier
by Drummond et al. [2]. It was pointed out that
the situation in Europe is characterized by its di-
versity. First, a wide range of health care systems
exist, including both “socialized” national health
services, such as those in Scandinavia and the
United Kingdom, and “liberal” systems, involving
a wide range of insurers and providers, more com-
mon in southern and central Europe.
Secondly, European countries differ widely in
their approaches to the pricing and reimbursement
of pharmaceuticals. Drummond et al. [3] dis-
cussed four different approaches. For example,
some countries such as the United Kingdom allow
free pricing of drugs by companies but regulate
profits. Other countries such as France operate a
two-stage administered system where an assess-
ment of the therapeutic equivalence (to other ex-
isting products) is made first and then price is ne-
gotiated depending on the classification of the
product.
There is also a growing interest in Europe in
reference-based pricing, in which drugs are assigned
to groups or “clusters” depending on assessments of
pharmacological or therapeutic equivalence. A ref-
erence price (or reimbursement level) is then set for
the cluster as a whole, although the manufacturer
is free to set the price at or above the reference
price. This approach exists in Denmark, Norway,
Germany, Sweden, and The Netherlands; only in
Germany and The Netherlands has clustering been
extended beyond pharmacological equivalence.
By contrast, in some countries such as Italy
prices are set according to comparison with those
existing in a group of other countries, and the
level of reimbursement is set according to the clin-
ical importance of the drug.
At the time of the earlier article, Drummond et
al. [2] reported that no European jurisdiction for-
mally required economic evaluation as a basis for
pricing or reimbursement decisions. Recently, how-
ever, a number of European Countries have indi-
cated that formal requirements will be introduced
or are under consideration. Also, in a number of
countries, guidelines for undertaking pharmaeco-
nomics studies have been proposed either by the
authorities or by academic researchers.
Therefore the purpose of this paper is to revisit
the earlier analysis of Drummond et al. [2], given
the changes that have taken place. It considers the
following issues:
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• Are economic evaluations officially required in
any country?
• Are there any other statements or guidance
from the authorities (e.g., government, sick-
ness funds, or insurers) relating to the need for
economic evaluation of health technologies?
• Do any published guidelines exist for eco-
nomic evaluation in European countries?
• What is the current practice of economic eval-
uation of pharmaceuticals in the various coun-
tries, and what are the major trends?
• What are the major uses of studies: price nego-
tiation, reimbursement decisions, local formu-
lary decisions, developing practice guidelines,
communicating to prescribers?
 
Methods
 
The study concentrated on 13 western European
countries, including 11 countries of the European
Union. Together these represented most, if not all,
of the major pharmaceutical markets outside the
United States and Japan and included all countries
where we expected any substantial activity in
pharmacoeconomics and outcomes research. The
focus was on full economic evaluations, that is,
studies comparing the costs and outcomes of drug
therapies in terms of improved health [4]. The
broader range of outcomes research studies, in-
cluding quality of life studies, burden of disease
studies, and analyses of databases was not consid-
ered. Such studies are often included in company
submissions to pricing or reimbursement agencies.
However, while containing relevant information,
they do not address value for money directly and
do not comply with the guidelines for economic
evaluations currently being promulgated by reim-
bursement authorities.
In each country, the study coordinators (the co-
authors of this paper) completed a questionnaire
covering the issues outlined above. No guidance
was given on the sources to be consulted when
completing the questionnaire, but it was expected
that the coordinators would rely heavily on the
published literature and their own local knowl-
edge. Each coordinator was a prominent health
economist in the country concerned.
No comprehensive surveys of decision-makers
or users of pharmacoeconomics and outcomes re-
search studies were carried out for this study, al-
though some coordinators were able to make use
of surveys recently conducted as part of the Euro-
pean Union Concerted Action on the Methodol-
ogy of Economic Evaluation of Health Technol-
ogy (EUROMET Project—Project Leader, Professor
Graf von der Schulenburg). Where such surveys
were available (in Finland, Germany, The Nether-
lands, Portugal, Spain, Sweden, and the United
Kingdom), the results were able to provide some
validation of the findings presented here. Other co-
ordinators relied on informal discussions with col-
leagues and key officials to validate their findings.
To determine the current practice of economic
evaluation in the various countries, study coordi-
nators were asked to give examples of up to five
landmark studies of economic evaluations of phar-
maceuticals conducted since 1993. In addition the
OHE-HEED database [1] was searched in order to
determine the total number of economic evalua-
tions conducted and the analytic methods used.
All the responses were collated and analyzed by
the first author and the report produced. No ex-
ternal funding was sought and the views expressed
are solely those of the authors.
 
Results
 
Official Requirements for Economic Studies
 
A number of the countries included have now in-
dicated that studies are required, or may be re-
quired, in the future. In The Netherlands the Sick-
ness Insurance Fund Council (Ziekenfondsraad)
has announced that from mid-1999, economic
evaluations will be required for new drugs not
covered by the reference price system. In practice
this means innovative new compounds for which
there is no near equivalent, or compounds for
which the manufacturer claims better effectiveness
and hence a premium price.
In Portugal, a new decree law (305/98) states
that Infarmed, the drug reimbursement agency,
may request economic evaluations whenever it
deems these necessary for decisions about the re-
imbursement of pharmaceuticals.
In Finland, from the beginning of 1998 an offi-
cial requirement came into effect that an applica-
tion to the Pharmaceuticals Pricing Board (PPB) by
a company for a “reasonable wholesale price”
must be accompanied by an economic evaluation
of the product. This evaluation should provide a
detailed and credible assessment of the costs and
benefits attainable by treatment with the new drug
in relation to the costs and benefits of other treat-
ments available both to the patient and to the
health and social services. The wholesale price en-
dorsed by the PPB serves as the basis for the basic
reimbursement by the National Sickness Insurance.
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In Denmark, pharmaceutical companies can
now submit economic evaluations to the Danish
Medicines Agency (Laegemiddelstyrelsen) when
they apply for reimbursement of new products.
This is in the context of a two-year agreement be-
tween the Pharmaceutical Industry Association
(Laegemiddelindustriforeningen) and the Minis-
try of Health imposing a ceiling on pharmaceuti-
cal expenditures, and followed the rejection by
both parties of a more formal arrangement. The
voluntary arrangement will be evaluated over a
3-to-5 year period.
In the United Kingdom, the Department of
Health has established a National Institute for
Clinical Excellence (NICE). This will identify ap-
proximately 30 new health technologies per year
for detailed assessment. In the case of pharmaceu-
ticals the company will be asked to provide data.
On the basis of its assessments, NICE will issue
guidelines for the appropriate use of health tech-
nologies, including pharmaceuticals, within the
UK National Health Service.
Finally, two countries are exploring the poten-
tial value of economic evaluation in making deci-
sions about pharmaceuticals. In Spain, the Minis-
try of Health has commissioned a study to assess
the interest and feasibility of introducing eco-
nomic evaluation into the procedures for pricing
and reimbursement of new pharmaceuticals. In
France, a special expert committee has been estab-
lished to review economic studies that are submit-
ted by companies to the Transparency Commis-
sion (which decides reimbursement status) or the
Price Committee (which determines price). Its first
task will be to examine past decisions in order to
assess the extent to which the information pro-
vided by studies could have assisted in the reim-
bursement or pricing decision.
 
Other Official Guidance About the Economic 
Evaluation of Health Technologies
 
A small number of countries are edging towards
formal requirements for economic evaluation of
pharmaceuticals on the Australian model. With
the possible exception of the United Kingdom, Eu-
ropean countries with large pharmaceutical mar-
kets have so far shied away from formal require-
ments.
There is evidence from other official state-
ments, however, that governments and third-party
payers are taking economic considerations seri-
ously. In Italy, the National Committee of Drugs
(Commissione Unica del Farmaco) lists pharmaco-
economics as one of the points to be considered in
submitting approval dossiers for innovative drugs.
Also, the Italian Committee for Economic Plan-
ning (Comitato Interministeriale Pianificazione
Economica) mentions cost-effectiveness ratios as a
criterion for price negotiations for innovative
drugs.
In Spain, there are generic statements in some
pieces of legislation relating to the reimbursement
of drugs and health technologies. Administrative
prices of drugs should officially be based on the
cost of production plus a profit mark-up. How-
ever, statements refer to situations of dominance;
that is, a given technology cannot be reimbursed if
there are others available of the same or higher
quality at a lower price.
In Germany, the Social Security Law states that
“treatments should be produced economically,”
otherwise these treatments cannot be reimbursed
by sickness funds. However, the law does not say
what is meant by economical, nor does it indicate
the methods by which it is to be assessed. Never-
theless, the new Social Democrat government has
indicated that economic considerations and evalu-
ations will play an important role in formulating
the planned positive list. This list will be devel-
oped by the Council of the Sickness Funds and In-
surance Doctors.
In Switzerland, the Federal Social Insurance Of-
fice has issued a manual on Standardization of
Clinical and Economic Evaluation of Medical
Technology, which regulates the procedure for
health insurance coverage. However, currently
pharmaceuticals are excluded from this. In The
Netherlands, the use of economic evaluation is
well-established in making decisions about health
insurance coverage for new health technologies [5].
Statements about the need for cost-effectiveness
in health care can also be found in official reports
in Portugal, Norway, Denmark, and the United
Kingdom. Their precise impact, other than setting
the general tone for discussion, however, is un-
clear.
 
Methodological Guidelines for
Economic Evaluation
 
Methodological guidelines exist in a number of
European countries. Sometimes they are linked to
an official requirement for economic evaluation as
in The Netherlands. Sometimes they arise from a
more general concern about the maintenance of
methodological standards. In Table 1, existing
guidelines are classified by their source (govern-
ment or academia) and their purpose. In some
cases, such as in Belgium and Germany, the
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groups developing guidelines had broad member-
ship from government, industry, and academia. In
such cases, the classification has been made ac-
cording to the main actor driving the discussion
and publishing the guidelines, i.e., the Belgian So-
ciety for Pharmacoepidemiology in Belgium, and
the University of Hannover in Germany.
Detailed examination of the various guidelines
indicates that there are some minor differences in
the methodological advice given, but there are
many similarities, for example in guidance on the
perspective to be adopted, the choice of compara-
tor regimen and the discount rate to be used. In
addition to the published guidelines listed in Table
1, discussions have taken place in Norway, Swe-
den, Italy, and the United Kingdom on this general
topic. However, none of these discussions has yet
resulted in published guidelines. Guidelines are
promised by the PPB in Finland in support of the
formal requirement for economic evaluation, al-
though these have not appeared to date.
 
Current Practice of Economic Evaluation of 
Pharmaceuticals in Europe
 
A number of economic evaluations have been con-
ducted in all of the 13 countries studied here. The
landmark studies identified by the study coordina-
tors are listed in the Appendix. These cover a wide
range of health care conditions and pharmaceuti-
cal products.
In addition, a fuller picture of trends in phar-
macoeconomics in Europe can be obtained from
the Health Economic Evaluation Database (HEED)
[1]. This lists more than 10,000 items, comprising
empirical studies (economic evaluations and qual-
ity of life studies), methodology papers, costing
studies, and reviews and editorials. Table 2 shows
the empirical studies of pharmaceuticals (classified
by form of economic evaluation) for the 13 coun-
tries considered here, for the three years 1995,
1996, and 1997. It should be noted that the cover-
age of the database is much more comprehensive
for the English-language literature than others.
Therefore it does not fully reflect pharmacoeco-
nomic activity in some countries but does give a
general flavor of the research being undertaken.
Table 3 shows the disease areas covered in
pharmacoeconomic studies for all 13 countries. In
every one the major funder of studies to date has
been the pharmaceutical industry, although in
Denmark, Germany, The Netherlands, Sweden,
Switzerland, and the United Kingdom, a minority
of studies have been funded by the government or
third-party payers.
A wide range of individuals and groups actually
conduct the studies, including academic centers,
private consultancies, clinicians, and pharmaceuti-
cal companies. Both trial-based and modeling
studies are conducted, although the latter are in
the majority in most countries. Often this is be-
cause there is a need to adapt, through a model,
data from elsewhere to the country concerned.
Many studies are published in all countries, al-
though the motivations of the various parties may
differ. For example, in settings in which studies
are used in negotiations about price or reimburse-
ment, there may be no perceived additional benefit
 
Table 1
 
Existence of economic evaluation guidelines
 
Source Pricing or Reimbursement Maintenance of Methodological Standards
Government or Payers Sickness Fund Council (NL) Department of Health (with the ABPI) (UK)
Infarmed (P)
Academia Alban et al (on behalf of the Ministry of Health) (DK) British Medical Journal (UK)
Alban et al (on behalf of the Ministry of Health) (DK)
College of Economists (F)
BESPE (B)
Hannover Consensus (D)
Garattini et al (I)
Rovira et al (E)
 
B 
 

 
 Belgium; D 
 

 
 Germany; DK 
 

 
 Denmark; E 
 

 
 Spain; F 
 

 
 France; I 
 

 
 Italy; NL 
 

 
 The Netherlands; P 
 

 
 Portugal; UK 
 

 
 The United Kingdom.
 
Table 2
 
Forms of economic evaluation used in European 
pharmacoeconomic studies
 
Type of Economic Evaluation Number of Studies (N 
 

 
 541)*
Cost of illness 59
Cost analysis 108
Cost-minimization analysis 54
Cost-consequences analysis 209
Cost-effectiveness analysis 231
Cost-utility analysis 54
Cost-benefit analysis 5
 
*Analysis based on 541 studies. Some studies used more than one form of
economic evaluation.
 
Source:
 
 OHE-IFPMA HEED [1]
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on the part of the individual pharmaceutical com-
pany from making the study more widely avail-
able. When studies are undertaken for marketing
purposes, however, publication in a good quality
journal is often seen as a major asset. Also, aca-
demic centers may expect or require publication of
the study as part of their agreement to participate,
whereas company authors or those from private
consultancies may regard wider publication as de-
sirable but not essential.
 
Uses of Economic Evaluations
 
There are a number of potential uses for economic
evaluations, both at the national and local level.
These are discussed below. However, it should be
recognized that the nature of the decision-making
process, and the confidentiality that often sur-
rounds it, sometimes makes it difficult to identify
the precise contribution made by a particular study.
Also, it should be recognized that the various
decision-making functions such as pricing and re-
imbursement may be handled by different com-
mittees, whereas economics would implicitly link
them. That is, in an economic model of decision-
making, whether or not a particular drug is pur-
chased or reimbursed, depends on its value for
money and hence price. This potential link some-
times blurs the precise contribution made by a
given economic study.
 
Reimbursement.
 
As mentioned above, it is often
difficult to disentangle pricing and reimbursement
decisions even though they are often made by dif-
ferent committees. Indeed, in Sweden and Finland,
pricing and reimbursement decisions are made by
the same committee.
When a formal role is prescribed for economic
evaluation, it is usually in the context of reim-
bursement, because in those countries where there
is price regulation, this decision is usually made
before the price negotiation. Also, the reimburse-
ment decision often includes a recommendation
about whether a given product should attract a
premium price. Thus, the economic evaluation
seeks to establish that there are additional eco-
nomic benefits from the new drug, over and above
existing treatment alternatives, that would justify
a premium.
In France, 72 health economic studies have
been submitted to the Transparency Commission
over the past 6 years. However, the majority are
either cost of illness studies (26) or cost identifica-
tion studies (20). Only 16 are economic evalua-
tions, comparing both costs and consequences.
The impact of studies has so far been limited, al-
though there are a few examples of situations in
which the study has affected the ranking of the
new drug on the scale used to establish a hierarchy
among innovations. For example, Le Pen [6] cites
one case in which a drug (sparfloxacine) was not
classed as a major innovation but was reimbursed
at a premium price, possibly partly as a result of
an economic study that was submitted.
In Spain, the only known example of an eco-
nomic evaluation being formally considered is a
study of centoxin [7]. The drug was only reim-
bursed for the more restrictive indication of septic
shock, whereas in many European countries it was
reimbursed for the broader indication of sepsis.
The economic evaluation may have influenced this
decision, although overall budgetary impact was
probably a more important factor.
Due to the voluntary arrangement in Denmark,
it has been possible since March 1997 to include
information from economic evaluations as part of
the decision-making process on the reimbursement
of new products. This requires that the pharma-
ceutical companies submit an economic evaluation
together with the ordinary application for reim-
bursement.
In Belgium, economic evaluation has played a
role in setting the criteria for the reimbursement of
vaccination (e.g., for hepatitis B) within Belgian
regional care programs.
 
Table 3
 
Disease areas studied in European 
pharmacoeconomic studies (by ATC classification)
 
Disease Area Number of Studies (N 
 

 
 541)*
Alimentary tract and metabolism 50
Blood and blood forming organs 46
Cardiovascular system 28
Dermatologicals 16
Genito-urinary system and 
sex hormones
15
Systematic hormonal preparations
excluding sex hormones
28
General antiinfectives for 
systematic use
130
Antineoplastic and 
immunomodulating agents
71
Musculo-skeletal system 17
Nervous system 74
Antiparasitic products, 
insecticides and repellents
4
Respiratory system 20
Sensory organs 0
Various 31
No code assigned 35
 
*Analysis based on 541 studies. In some studies more than one code was
assigned.
 
Source:
 
 OHE-IFPMA HEED [1]
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Although formal economic evaluation require-
ments are being introduced in Finland, The Nether-
lands, and Portugal, the key issue in most countries
is still assessment of the clinical equivalence of the
drug or otherwise with existing alternatives. There-
fore, an innovative drug with no obvious compara-
tors always has a higher probability of attracting a
premium price. As mentioned above, a potential
role for economic evaluation is to explore the range
within which that premium might fall.
 
Price Negotiations.
 
In general, the use of eco-
nomic evaluation in price negotiations is limited
and there are no formal requirements. In Switzer-
land and France, manufacturers have presented
economic data to pricing committees without
knowing the likely impact. Indeed, in France the
Price Committee states that the pricing process is
multifactorial and will not depend on the results
of an economic study. In Sweden, studies are ac-
cepted by the National Social Insurance Board as
a basis for consultation on price. In Norway, the
pharmacoeconomics unit of the Medicines Con-
trol Authority (Statens Legemiddel-Kontroll) pro-
duces a number of reports but these are not in the
public domain. Finally, in Italy the recent equal
drugs–equal prices rule, introduced by CUF in
1997, may have increased the use of pharmacoeco-
nomic studies to justify premium prices.
To the extent that pharmacoeconomics studies
help differentiate new products from existing ones,
they may justify premium prices. Nevertheless, as
Drummond et al. [7] argue, the final price for a drug
will always be subject to negotiation. This negotia-
tion establishes the proportion of any economic
gain to be returned to the company, rather than
given to society more generally. The most a phar-
macoeconomic study can contribute is to delineate
a range of prices within which a new drug is po-
tentially good value for money.
 
Local Formulary Discussions.
 
In most of the
countries studied, formularies exist at the hospital
level. In a minority of countries they also exist at
the level of the physician group practice (as in the
United Kingdom) or at the level of the local au-
thority such as the Regional Formulary Commit-
tees in The Netherlands, and the County Councils
in Denmark and Sweden.
Evidence of the use of economic evaluation in
formulary discussions is difficult to show, given
the large number of local decision-making groups
that would be difficult to survey systematically.
However, the study coordinators from The Neth-
erlands, the United Kingdom, Denmark, and Ger-
many provided evidence of the use of economic
studies in formulary decision-making. In Sweden,
the drug formulary committees of the county
councils are required by law to take economic as-
pects into account when selecting a drug. It is also
likely that economic criteria are applied infor-
mally in a much wider range of local settings.
 
Developing Clinical Practice Guidelines.
 
In a num-
ber of European countries the development of evi-
dence-based clinical practice guidelines is becom-
ing increasingly popular. The vast majority of
these consider clinical evidence alone and indeed
the inclusion of economic data may cause tension
[8]. Nevertheless, the study coordinators did iden-
tify examples of guidelines incorporating cost-
effectiveness evidence in a number of countries.
In Sweden, economic studies in the fields of hy-
pertension and hyperlipidemia have been cited in
the development of practice guidelines. In The
Netherlands, it was recommended in a guideline
from the Dutch hemato-oncology group, that
GM-CSF should not be used in patients with ther-
apy-induced neutropenic fever as a result of an
economic evaluation. Also, the economic evalua-
tions of statins in primary and secondary preven-
tion of hyperlipidemia were influential in deter-
mining which risk groups should receive therapy.
It was decided that only those groups for which
the incremental cost-effectiveness ratio was less
than or equal to 40,000 NLG (Netherlands Guil-
ders) per life-year gained should receive treatment.
In Germany, the sponsor of an economic evalu-
ation of the cost-effectiveness of combination ther-
apy for asthma is seeking to have this included in
treatment guidelines being developed by the Ger-
man Association of Pneumologists. In Denmark,
an economic study of a screening and treatment
program for children with urinary tract infections
was carried out at the request of the National
Board of Health (Sundhedsstyrelsen) and was taken
into account when developing the model health
care program for this condition [9]. Finally, in the
United Kingdom, as part of the Evidence Based
Outreach (EBOR) project funded by the Depart-
ment of Health, economic considerations have been
taken into account in developing prescribing guide-
lines in the areas of ACE inhibitors for symptomatic
heart failure, NSAIDs in arthritis, drugs for treat-
ment of depression, and antiplatelet therapy [10].
The experience gained in developing these guide-
lines has also thrown some light on the broader is-
sues involved with incorporating economic evalu-
ation into practice guidelines [11].
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Communications to Prescribers.
 
The pharmaceu-
tical industry has traditionally viewed communi-
cations to prescribers as one of its most powerful
marketing tools. The same view has been taken by
some governments, which now invest a consider-
able amount of resources in informing prescribers
about the relative merits and demerits of particu-
lar drugs.
Communications to prescribers tend to concen-
trate on efficacy and safety of medicines, but some
do include economic data. For example, in the
United Kingdom the publications from the Drug
and Therapeutics Bulletin and the Medicines Re-
source Centre (MeReC) usually mention the com-
parative costs of medicines, although they rarely
discuss formal economic evaluations. The same
approach is used by Infarmed and the Regional
Health Authorities in Portugal. In Sweden, the
Medical Products Agency conducts workshops
and communicates the results through publica-
tions. In The Netherlands, considerable effort goes
into disseminating consensus guidelines, some of
which contain pharmacoeconomic information to
general practitioners and medical specialists. For
example, the cholesterol guidelines are now being
communicated to GPs and cardiologists.
Finally, in Norway the Medicines Control Au-
thority used a study to discourage doctors from
prescribing an osteoporosis drug (alendronate) on
the basis of cost considerations. However, the sci-
entific content of the study was disputed by the
drug’s manufacturer in the courts.
In general, very little is known about the impact
of communicating pharmacoeconomic data to pre-
scribers and this is clearly an area for further re-
search. One would suspect, however, that a critical
question is whether the prescriber perceives him or
herself as responsible for a defined drugs budget, as
budgetary initiatives in the United Kingdom and
Germany have previously shown.
 
Overall Position.
 
The overall position regarding
the use of economic evaluation of pharmaceuticals
is extremely varied. This position is summarized in
Table 4. An asterisk indicates that there is some
evidence of the use of economic evaluation in the
particular function or activity in the country con-
cerned. However, it is important to remember
that, since most of the discussions in pricing, reim-
bursement, and formulary committees are not
made public, it is difficult to produce clear exam-
ples. Nevertheless, our impression is that value for
money criteria are applied informally in many
such discussions.
 
Conclusions
 
The situation with regard to the practice and poten-
tial for pharmacoeconomics and outcomes research
varies among the 13 European countries studied.
Different countries have different approaches to
making pricing and reimbursement decisions and
the formal evidence for use of pharmacoeconomic
studies is unclear.
However, more European countries are intro-
ducing formal requirements for economic evalua-
tion of new medicines, particularly in the case of
innovative products, or in situations in which the
manufacturer is seeking a premium price.
There are a number of guidelines for economic
evaluation in Europe, some linked to the formal
requirements for studies and some having the
more general objective of maintaining or improv-
ing methodological standards. In general, the simi-
 
Table 4
 
Use of economic evaluation of pharmaceuticals in 13 European countries
 
Reimbursement 
decisions
Price 
negotiations
Local formulary 
discussions
Developing clinical
practice guidelines
Communications
to prescribers
Belgium * * *
Denmark * * *
Finland * * *
France * *
Germany * * *
Italy *
Netherlands * * * *
Norway * * *
Portugal * *
Spain *
Sweden * * * * *
Switzerland * *
United Kingdom * * *
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larities among the guidelines outweigh the differ-
ences. Overall, methodologies employed in studies
and current methodological debates are similar to
those that are ongoing in North America.
Beyond the formal requirements for studies, dif-
ferent countries employ a range of mechanisms for
encouraging the cost-effective use of medicines, in-
cluding reference-based pricing and education of
physicians in economics. If any trend is emerging, it
seems that in a growing number of countries major
innovative products are likely to be subjected to
formal economic evaluation, whereas cost-effec-
tiveness in the use of the vast majority of medicines
will be achieved through other means.
Although it is difficult to obtain clear evidence
of the use of pharmacoeconomic studies in differ-
ent settings due to the lack of transparency in deci-
sion-making procedures, the trend is toward more
use rather than less. It is also likely that the infor-
mal application of value for money principles ex-
tends beyond the use of studies. In general, the use
of pharmacoeconomic and outcomes research is
expanding in Europe, although the pace of change
differs from one country to another. Perhaps the
greater use of economic evaluation, and the devel-
opment of formal guidelines or requirements, may
lead to greater transparency in the decision-mak-
ing procedures themselves.
 
An earlier version of this paper was presented at the In-
augural ISPOR European Conference, Köln, 11 Decem-
ber 1998. The authors are grateful to the Steering Group
of the EUROMET Project for permission to use data col-
lected as part of that study. No additional funding was
sought for the study beyond the support offered by our
own organizations. Finally, we are grateful to Julie Glan-
ville for the literature review, Vanessa Windass for manu-
script preparation, and anonymous referees for sugges-
tions made.
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